

JC10 Rec'd PCT/PTO 08 JUL 2005 PC

ED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Del Soldato

Group Art Unit: Unknown

Patent Application Serial No.: 10/509,675 Examiner: Unknown

Filed: October 8, 2004

Attorney Docket No.: 026220-00055

For: Drugs for the Arthritis Treatment

July 8, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97, and 1.98, the applicant respectfully directs the attention of the U.S. Patent and Trademark Office to the documents listed on the attached Forms PTO-SB/08a and SB/08b.

GB 1,195,628 (Reference AR) is the English language equivalent of FR 1,574,570, which the applicant does not include. GB 1,519,811 (Reference AS) is the English language equivalent of DE 2,537,070, which the applicant also does not include.

The applicant respectfully requests that the information be considered during the prosecution of this application, the items be made of record therein, and that the references appear among the "References Cited" on any patent issuing therefrom. The applicant further requests that the attached Forms PTO-SB/08a and SB/08b be initialed and return to the undersigned.

This Information Disclosure Statement is filed pursuant to 37 C.F.R. §1.97(b)(3), i.e., before the mailing of a first office action on the merits. Therefore, the applicant

U.S. Patent Application No.: 10/509,675

inventor(s): Del Soldato

Attorney Docket No.: 026220-00055

believes that no fee is due for the consideration of this information. The Commissioner is authorized to charge any fee deficiencies, or credit any over-payments, to Deposit Account No. 01-2300, referencing Attorney Docket No. 026220-00055.

Respectfully submitted,

ARENT FOX PLLC

Gautam Prakash, Ph.D. Registration No.: 53,481

Direct Telephone No.: 202-857-6057

Customer No.: 004372

1050 Connecticut Avenue, N.W. Washington, D.C. 20036-5339

Telephone No.: 202-857-6000 Facsimile No.: 202-857-6395

/GP

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork reduction Act of 1995, https://doi.org/10.1007/10.1

INFORMATION DISCLESS STATEMENT BY APPLIC	URES	\
STATEMENT BY APPLIC	ANT	V
Form PTO/SB/08a	. a M	

Complete if Known

Application Number 10/509,675

Filing Date October 8, 2004

First Named Inventor DEL SOLDATO

Art Unit

			1 1 - 1	ا 'دي	Exam	iner Name		
Sheet		1	of 1	رڅ:		ey Docket Number	026220-0005	5
		·-	CV C TO LOS	PA'	TENT	DOCUMENTS Name of Par		
Examiner Initials*	Cite No.1	Document Number	Number-Rind Code ² (if known)	MM-DD-YYYY		Name of Par Applicant of Cite		Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appear
	AA	US- 2,998,450		08/29/	1961_	Wilbert et al.		
	AB	US- 3,161,654		12/15/	1964	Shen	,	
	AÇ	US- 3,591,584		07/06/	1971	Lombardino		
	AD	US- 3,600,437		08/17/	1971	Marshall		
	AE	US- 3,784,701		01/08/	1974	Tomcufcik et al.		
	AF	US- 3,843,681		11/22/	1974	Demerson et al.		
	AG	US- 3,997,669		12/14/	1976	Carney et al.		
	AH	US- 4,035,376		07/12/	1977	Janssen et al.		
	Al	US- 4,061,779		12/06/	1977	Lake et al.		
	AJ	US- 4,161,538		07/17/	1979	Terada et al.		
							,	
	1							
					-			
-	\vdash			† • • • • • • • • • • • • • • • • • • •				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Country Code ³	Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	AK	WO 94/04484	WO	A1	03/03/1994	Matji et al.		
	AL	WO 94/12463	WO	A1	06/09/1994	Arena		
	AM	WO 95/30641	wo	A1	11/16/1995 -	Del Soldato et al.		
	AN	WO 97/16405	wo	A1	05/09/1997	Del Soldato et al.		
	AO	WO 98/09948	wo	A2	03/12/1998	Del Soldato et al.		
	AP	WO 00/61537	wo	A2	11/19/2000	Del Soldato et al.		
	AQ	WO 01/12584	WO	A2	02/22/2001	Del Soldato et al.		
	AR	1,195,628	GB		06/17/1970	Carson		
	AS	1,519,811	GB		08/02/1978	Hromatka et al.		
	<u> </u>			<u> </u>				┼
Examiner Signature						Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduced Act of 1995 persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

1

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO/SB/08b

of

	Complete if Known
Application Number	10/509,675
Filing Date	October 8, 2004
First Named Inventor	DEL SOLDATO
Art Unit	
Examiner Name	
Attorney Docket Number	026220-00055

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	АТ	RASHAD et al., "Effect of Non-Steroidal Anti-Inflammatory Drugs on the Course of Osteoarthritis", Lancet Ltd. 519-522, 1989.	
	AU	FELISAZ et al., "Stimulating effect of diacerein on TGF-ß1 and ß2 expression in articular chondrocytes cultured with and without interleukin-1", Osteoarthritis and Cartilage 7, 255-267, 1999.	
	AV	BOUMEDIENE et al., "Decrease of cartilage transforming growth factor-ß receptor II expression in the rabbit experimental osteoarthritis-potential role in cartilage breakdown", Osteoarthritis and Cartilage 6, 146-149, 1998.	
	AW	CHOY et al., "Therapeutic Benefit of Blocking Interleukin-6 Activity With an Anti-Interleukin-6 Receptor Monoclonal Antibody in Rheumatoid Arthritis ", Arthritis & Rheumatism 46(12), 3143-3150, 2002.	-
	AX	BENYA et al., "The Progeny of Rabbit Articular Chondrocytes Synthesize Collagen Types I and III and Type I Trimer, but Not Type II. Verifications by Cyanogen Bromide Peptide Analysis", <i>Biochemistry</i> 16(5) , 865-872, 1977.	
	AY	JENNINGS <i>et al.</i> , "Comparison of the Biological Actions of TGF Beta-1 and TGF Beta-2: Differential Activity in Endothelial Cells", <i>J. Cellular Physiol.</i> 137 , 167-172, 1988.	
	AZ	Martindale The Extra Pharmacopoeia, Thirty-first Edition (Reynolds, J.E. Ed.), 1996, pp. 11-13	_
	ВА	Martindale The Extra Pharmacopoeia, Thirty-first Edition (Reynolds, J.E. Ed.), 1996pp. 299-300	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.